Patient distrust in pharmaceutical companies: an explanation for women under-representation in respiratory clinical trials?
Clinical trials
External validity
Patients’ distrust
Recruitment bias
Under-representation of women
Journal
BMC medical ethics
ISSN: 1472-6939
Titre abrégé: BMC Med Ethics
Pays: England
ID NLM: 101088680
Informations de publication
Date de publication:
13 08 2020
13 08 2020
Historique:
received:
16
09
2019
accepted:
23
07
2020
entrez:
15
8
2020
pubmed:
15
8
2020
medline:
29
7
2021
Statut:
epublish
Résumé
Patient skepticism concerning medical innovations can have major consequences for current public health and may threaten future progress, which greatly relies on clinical research. The primary objective of this study is to determine the variables associated with patient acceptation or refusal to participate in clinical research. Specifically, we sought to evaluate if distrust in pharmaceutical companies and associated psychosocial factors could represent a recruitment bias in clinical trials and thus threaten the applicability of their results. This prospective, multicenter survey consisted in the administration of a self-questionnaire to patients during a pulmonology consultation. The 1025 questionnaires distributed collected demographics, socio-professional and basic health literacy characteristics. Patients were asked to rank their level of trust for pharmaceutical companies and indicate their willingness to participate in different categories of research (pre or post marketing, sponsored by an academic institution or pharmaceutical company). Logistic regression was used to determine factors contributing to "trust" versus "distrust" group membership and willingness to participate in each category of research. One thousand patients completed the survey, corresponding to a response rate of 97.5%. Data from 838 patients were analyzed in this study. 48.3% of respondents declared that they trusted pharmaceutical companies, while 35.5% declared distrust. Being female (p = 0.042), inactive in the employment market(p = 0.007), and not-knowing the name of one's disease(p = 0.010) are factors related to declared distrust. Distrust-group membership is associated with unwillingness to participate in certain categories of trials such as pre-marketing and industry-sponsored trials. Distrust in pharmaceutical companies is associated with a specific patient profile and with refusal to participate in certain subcategories of trials. This potential recruitment bias may explain the under-representation of certain categories of patients such as women in pre-marketing drug trials.
Sections du résumé
BACKGROUND
Patient skepticism concerning medical innovations can have major consequences for current public health and may threaten future progress, which greatly relies on clinical research. The primary objective of this study is to determine the variables associated with patient acceptation or refusal to participate in clinical research. Specifically, we sought to evaluate if distrust in pharmaceutical companies and associated psychosocial factors could represent a recruitment bias in clinical trials and thus threaten the applicability of their results.
METHODS
This prospective, multicenter survey consisted in the administration of a self-questionnaire to patients during a pulmonology consultation. The 1025 questionnaires distributed collected demographics, socio-professional and basic health literacy characteristics. Patients were asked to rank their level of trust for pharmaceutical companies and indicate their willingness to participate in different categories of research (pre or post marketing, sponsored by an academic institution or pharmaceutical company). Logistic regression was used to determine factors contributing to "trust" versus "distrust" group membership and willingness to participate in each category of research.
RESULTS
One thousand patients completed the survey, corresponding to a response rate of 97.5%. Data from 838 patients were analyzed in this study. 48.3% of respondents declared that they trusted pharmaceutical companies, while 35.5% declared distrust. Being female (p = 0.042), inactive in the employment market(p = 0.007), and not-knowing the name of one's disease(p = 0.010) are factors related to declared distrust. Distrust-group membership is associated with unwillingness to participate in certain categories of trials such as pre-marketing and industry-sponsored trials.
CONCLUSION
Distrust in pharmaceutical companies is associated with a specific patient profile and with refusal to participate in certain subcategories of trials. This potential recruitment bias may explain the under-representation of certain categories of patients such as women in pre-marketing drug trials.
Identifiants
pubmed: 32791969
doi: 10.1186/s12910-020-00509-y
pii: 10.1186/s12910-020-00509-y
pmc: PMC7424561
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
72Références
J Empir Res Hum Res Ethics. 2016 Feb;11(1):21-30
pubmed: 26928896
BMJ. 2003 May 31;326(7400):1171-3
pubmed: 12775615
Eur Respir J. 2017 Aug 24;50(2):
pubmed: 28838976
Eur J Public Health. 2006 Feb;16(1):4-6
pubmed: 16446297
JAMA. 2005 Sep 21;294(11):1333-42
pubmed: 16174691
BMJ. 2003 May 31;326(7400):1167-70
pubmed: 12775614
Pharmacoepidemiol Drug Saf. 2007 Jan;16(1):28-31
pubmed: 17177322
Gynecol Oncol. 2016 Sep;142(3):520-4
pubmed: 27372403
Clin Ther. 2017 Jan;39(1):23-33
pubmed: 28034518
Am Heart J. 2003 Dec;146(6):985-92
pubmed: 14660989
Health Technol Assess. 2004 Oct;8(42):iii, 1-109
pubmed: 15488164
J Relig Health. 2017 Apr;56(2):623-634
pubmed: 27631996
J Health Polit Policy Law. 1999 Jun;24(3):531-65
pubmed: 10386326
JAMA. 2002 Feb 13;287(6):772
pubmed: 11851548
BMJ. 2003 May 31;326(7400):1178-9
pubmed: 12775618
Clin Trials. 2019 Aug;16(4):440-442
pubmed: 30922104
N Engl J Med. 2014 Oct 23;371(17):1570-2
pubmed: 25337746
Health Care Women Int. 1998 May-Jun;19(3):243-60
pubmed: 9601305
BMJ. 2004 Jul 31;329(7460):247
pubmed: 15284128
PLoS One. 2010 Dec 16;5(12):e14368
pubmed: 21179556
JAMA Intern Med. 2014 Nov;174(11):1868-70
pubmed: 25264856
BMC Public Health. 2015 Jan 17;15:10
pubmed: 25595373
Am J Med Sci. 2016 Apr;351(4):387-99
pubmed: 27079345
Cochrane Database Syst Rev. 2007 Apr 18;(2):MR000021
pubmed: 17443636
Inflamm Bowel Dis. 2009 Aug;15(8):1233-9
pubmed: 19177509
BMJ Open. 2015 Apr 08;5(4):e006420
pubmed: 25854965
JAMA. 2016 Mar 15;315(11):1149-58
pubmed: 26978210
J Prev Med Hyg. 2015 Aug 05;56(2):E72-6
pubmed: 26789992
Am J Respir Crit Care Med. 2015 Jul 15;192(2):259-61
pubmed: 26177176
BMC Cancer. 2012 Dec 12;12:594
pubmed: 23234342
J Am Coll Cardiol. 2018 May 8;71(18):1960-1969
pubmed: 29724348
Acad Med. 2018 Apr;93(4):630-635
pubmed: 29053489
Trials. 2016 Jan 09;17:17
pubmed: 26745891